OncoMatch/Clinical Trials/NCT07353957
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Is NCT07353957 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Petosemtamab + Pembrolizumab for lung cancer - non small cell squamous.
Treatment: Petosemtamab + Pembrolizumab — The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Biomarker criteria
Required: PD-L1 (CD274) TPS ≥ 50% (TPS ≥ 50%)
PD-L1 TPS ≥ 50%
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-(L)1 inhibitor
Participants who received prior treatment with a PD-(L)1 inhibitor
Cannot have received: systemic chemotherapy
Participants who have received prior systemic chemotherapy, targeted or biological antineoplastic therapy for metastatic NSCLC
Cannot have received: targeted therapy
Participants who have received prior systemic chemotherapy, targeted or biological antineoplastic therapy for metastatic NSCLC
Cannot have received: biological antineoplastic therapy
Participants who have received prior systemic chemotherapy, targeted or biological antineoplastic therapy for metastatic NSCLC
Cannot have received: systemic anticancer therapy
Any systemic anticancer therapy within 4 weeks prior to the first dose of study treatment
Cannot have received: radiotherapy
Exception: Participants who received prior radiotherapy to ≥ 25% of bone marrow are not eligible, regardless of when it was received.
Major surgery or radiotherapy within 3 weeks prior to the first dose of study treatment. Participants who received prior radiotherapy to ≥ 25% of bone marrow are not eligible, regardless of when it was received.
Lab requirements
Blood counts
adequate hematologic function
Kidney function
creatinine clearance ≥ 60 ml/min calculated according to the cockroft and gault formula
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Tennessee Site 2 · Chattanooga, Tennessee
- Tennessee Site 1 · Nashville, Tennessee
- Virginia Site 1 · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07353957 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 TPS ≥ 50% is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify